Az FDG-PET prognosztikai értéke Hodgkin-lymphomás betegek követésében - hosszú távú eredményeink

Zsuzsa Molnár, Zsófia Simon, Zita Borbényi, Beáta Deák, L. Galuska, Kármen Keresztes, Zsófia Miltényi, Imelda Marton, András Rosta, Tamás Schneider, L. Trón, Erika Várady, A. Illés

Research output: Article

Abstract

In the past few decades Hodgkin lymphoma (HL) has become a highly curable malignant disease, as a result of using modern polychemotherapy and irradiation. Differentiation of active tumor from fibrosis or necrosis within residual radiographic masses represents a problem of interpretation. Aims: The aim of this retrospective study is to assess the value of FDG-PET for prediction of remission or relapse in HL. Patients and methods: Data of 128 patients, who had residual masses on CT after completion of their planned treatment, have been analyzed. FDG-PET was performed between January 1995 and February 2005. Results: The median duration of the follow-up from PET was 75.5 months (range: 20-180 months). 89 (70%) patients had negative and 39 (30%) patients had positive FDG-PET results. The numbers of true-positive, true-negative, false-positive and false-negative subjects were 29, 83, 10 and 6, respectively. Sensitivity of post-treatment FDG-PET was 83%, specificity 93%, positive predictive value 74%, negative predictive value 93%, and accuracy 88%. The difference between the event free survival of PET positive and negative cases is highly significant (p = 0.0000), according to the Mantel-Cox test. Conclusion: Our results, in accordance with literature, clearly indicate that patients with negative FDG-PET results are unlikely to progress or relapse during a long follow-up. However, false positive uptake is a problem. We have investigated the effect of age, histological subtype, clinical stage and the type of treatment on the accuracy, but on the basis of these facts we could not find any significant difference. However, the date of the investigation influenced the results: before 2000 the number of false results was significantly higher than after that time, which shows the importance of investigators' experience.

Original languageHungarian
Pages (from-to)2133-2138
Number of pages6
JournalOrvosi Hetilap
Volume150
Issue number47
DOIs
Publication statusPublished - 2009

Fingerprint

Hodgkin Disease
Recurrence
Combination Drug Therapy
Disease-Free Survival
Fibrosis
Necrosis
Therapeutics
Retrospective Studies
Research Personnel
Neoplasms

Keywords

  • FDG-PET
  • Hodgkin lymphoma
  • Hodgkin-lymphoma
  • Prognózis
  • Prognosis
  • Restaging

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az FDG-PET prognosztikai értéke Hodgkin-lymphomás betegek követésében - hosszú távú eredményeink. / Molnár, Zsuzsa; Simon, Zsófia; Borbényi, Zita; Deák, Beáta; Galuska, L.; Keresztes, Kármen; Miltényi, Zsófia; Marton, Imelda; Rosta, András; Schneider, Tamás; Trón, L.; Várady, Erika; Illés, A.

In: Orvosi Hetilap, Vol. 150, No. 47, 2009, p. 2133-2138.

Research output: Article

Molnár, Z, Simon, Z, Borbényi, Z, Deák, B, Galuska, L, Keresztes, K, Miltényi, Z, Marton, I, Rosta, A, Schneider, T, Trón, L, Várady, E & Illés, A 2009, 'Az FDG-PET prognosztikai értéke Hodgkin-lymphomás betegek követésében - hosszú távú eredményeink', Orvosi Hetilap, vol. 150, no. 47, pp. 2133-2138. https://doi.org/10.1556/OH.2009.28746
Molnár, Zsuzsa ; Simon, Zsófia ; Borbényi, Zita ; Deák, Beáta ; Galuska, L. ; Keresztes, Kármen ; Miltényi, Zsófia ; Marton, Imelda ; Rosta, András ; Schneider, Tamás ; Trón, L. ; Várady, Erika ; Illés, A. / Az FDG-PET prognosztikai értéke Hodgkin-lymphomás betegek követésében - hosszú távú eredményeink. In: Orvosi Hetilap. 2009 ; Vol. 150, No. 47. pp. 2133-2138.
@article{030b8088af0446e59f834355effc2c74,
title = "Az FDG-PET prognosztikai {\'e}rt{\'e}ke Hodgkin-lymphom{\'a}s betegek k{\"o}vet{\'e}s{\'e}ben - hossz{\'u} t{\'a}v{\'u} eredm{\'e}nyeink",
abstract = "In the past few decades Hodgkin lymphoma (HL) has become a highly curable malignant disease, as a result of using modern polychemotherapy and irradiation. Differentiation of active tumor from fibrosis or necrosis within residual radiographic masses represents a problem of interpretation. Aims: The aim of this retrospective study is to assess the value of FDG-PET for prediction of remission or relapse in HL. Patients and methods: Data of 128 patients, who had residual masses on CT after completion of their planned treatment, have been analyzed. FDG-PET was performed between January 1995 and February 2005. Results: The median duration of the follow-up from PET was 75.5 months (range: 20-180 months). 89 (70{\%}) patients had negative and 39 (30{\%}) patients had positive FDG-PET results. The numbers of true-positive, true-negative, false-positive and false-negative subjects were 29, 83, 10 and 6, respectively. Sensitivity of post-treatment FDG-PET was 83{\%}, specificity 93{\%}, positive predictive value 74{\%}, negative predictive value 93{\%}, and accuracy 88{\%}. The difference between the event free survival of PET positive and negative cases is highly significant (p = 0.0000), according to the Mantel-Cox test. Conclusion: Our results, in accordance with literature, clearly indicate that patients with negative FDG-PET results are unlikely to progress or relapse during a long follow-up. However, false positive uptake is a problem. We have investigated the effect of age, histological subtype, clinical stage and the type of treatment on the accuracy, but on the basis of these facts we could not find any significant difference. However, the date of the investigation influenced the results: before 2000 the number of false results was significantly higher than after that time, which shows the importance of investigators' experience.",
keywords = "FDG-PET, Hodgkin lymphoma, Hodgkin-lymphoma, Progn{\'o}zis, Prognosis, Restaging",
author = "Zsuzsa Moln{\'a}r and Zs{\'o}fia Simon and Zita Borb{\'e}nyi and Be{\'a}ta De{\'a}k and L. Galuska and K{\'a}rmen Keresztes and Zs{\'o}fia Milt{\'e}nyi and Imelda Marton and Andr{\'a}s Rosta and Tam{\'a}s Schneider and L. Tr{\'o}n and Erika V{\'a}rady and A. Ill{\'e}s",
year = "2009",
doi = "10.1556/OH.2009.28746",
language = "Hungarian",
volume = "150",
pages = "2133--2138",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "47",

}

TY - JOUR

T1 - Az FDG-PET prognosztikai értéke Hodgkin-lymphomás betegek követésében - hosszú távú eredményeink

AU - Molnár, Zsuzsa

AU - Simon, Zsófia

AU - Borbényi, Zita

AU - Deák, Beáta

AU - Galuska, L.

AU - Keresztes, Kármen

AU - Miltényi, Zsófia

AU - Marton, Imelda

AU - Rosta, András

AU - Schneider, Tamás

AU - Trón, L.

AU - Várady, Erika

AU - Illés, A.

PY - 2009

Y1 - 2009

N2 - In the past few decades Hodgkin lymphoma (HL) has become a highly curable malignant disease, as a result of using modern polychemotherapy and irradiation. Differentiation of active tumor from fibrosis or necrosis within residual radiographic masses represents a problem of interpretation. Aims: The aim of this retrospective study is to assess the value of FDG-PET for prediction of remission or relapse in HL. Patients and methods: Data of 128 patients, who had residual masses on CT after completion of their planned treatment, have been analyzed. FDG-PET was performed between January 1995 and February 2005. Results: The median duration of the follow-up from PET was 75.5 months (range: 20-180 months). 89 (70%) patients had negative and 39 (30%) patients had positive FDG-PET results. The numbers of true-positive, true-negative, false-positive and false-negative subjects were 29, 83, 10 and 6, respectively. Sensitivity of post-treatment FDG-PET was 83%, specificity 93%, positive predictive value 74%, negative predictive value 93%, and accuracy 88%. The difference between the event free survival of PET positive and negative cases is highly significant (p = 0.0000), according to the Mantel-Cox test. Conclusion: Our results, in accordance with literature, clearly indicate that patients with negative FDG-PET results are unlikely to progress or relapse during a long follow-up. However, false positive uptake is a problem. We have investigated the effect of age, histological subtype, clinical stage and the type of treatment on the accuracy, but on the basis of these facts we could not find any significant difference. However, the date of the investigation influenced the results: before 2000 the number of false results was significantly higher than after that time, which shows the importance of investigators' experience.

AB - In the past few decades Hodgkin lymphoma (HL) has become a highly curable malignant disease, as a result of using modern polychemotherapy and irradiation. Differentiation of active tumor from fibrosis or necrosis within residual radiographic masses represents a problem of interpretation. Aims: The aim of this retrospective study is to assess the value of FDG-PET for prediction of remission or relapse in HL. Patients and methods: Data of 128 patients, who had residual masses on CT after completion of their planned treatment, have been analyzed. FDG-PET was performed between January 1995 and February 2005. Results: The median duration of the follow-up from PET was 75.5 months (range: 20-180 months). 89 (70%) patients had negative and 39 (30%) patients had positive FDG-PET results. The numbers of true-positive, true-negative, false-positive and false-negative subjects were 29, 83, 10 and 6, respectively. Sensitivity of post-treatment FDG-PET was 83%, specificity 93%, positive predictive value 74%, negative predictive value 93%, and accuracy 88%. The difference between the event free survival of PET positive and negative cases is highly significant (p = 0.0000), according to the Mantel-Cox test. Conclusion: Our results, in accordance with literature, clearly indicate that patients with negative FDG-PET results are unlikely to progress or relapse during a long follow-up. However, false positive uptake is a problem. We have investigated the effect of age, histological subtype, clinical stage and the type of treatment on the accuracy, but on the basis of these facts we could not find any significant difference. However, the date of the investigation influenced the results: before 2000 the number of false results was significantly higher than after that time, which shows the importance of investigators' experience.

KW - FDG-PET

KW - Hodgkin lymphoma

KW - Hodgkin-lymphoma

KW - Prognózis

KW - Prognosis

KW - Restaging

UR - http://www.scopus.com/inward/record.url?scp=73949156832&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73949156832&partnerID=8YFLogxK

U2 - 10.1556/OH.2009.28746

DO - 10.1556/OH.2009.28746

M3 - Article

C2 - 19910278

AN - SCOPUS:73949156832

VL - 150

SP - 2133

EP - 2138

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 47

ER -